ESMO24 . SMALL CELL LUNG CÁNCER SEGUNDA LÍNEA . COMPARATIVA DE PFS PRESENTADAS : PFS CON YL_201 DE MEDLINK : 6,2 MESES . PFS CON IFINATAMAB DERUXTECAN DE MERCK : 5,5 MESES . PFS CON GSK_764227 DE GLAXO SMITH : 5,9 MESES .

 

" YL201, Which is As Yet Unpartnered, Looks Particularly Good in SECOND-LINE or Later SMALL-CELL LUNG CÁNCER " .

This Tumour Type Has  Recently Seen Data With Both Merck/Daiichi’s IFINATAMAB DERUXTECAN & GSK/Hansoh’s GSK5764227, Allowing a Handy Cross-Trial Comparison .

Data Released on Friday At ESMO24 Suggest That MediLink's B7-H4 Targeting Antibody-Drug Conjugates YL201 Could Be Competitive Against Candidates Originated By Daiichi Sankyo & Hansoh Pharma For Relapsed SMALL-CELL LUNG CÁNCER Wrote @ByMadeleineA .